Atlas Trials

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Clinical trial NCT03701022 · UNKNOWN

Trial details

NCT number
NCT03701022
Sponsor
Peking University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NK/T-cell Lymphoma
Start date
2018-10-20
Primary completion
2020-03-30
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.